Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

20
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
20
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

29
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
29
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

17
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
17
Dementia01:30

Dementia

148
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
148
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

26
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebral Microvascular Injury and Physical Function in Older Patients With Atrial Fibrillation: Evidence for Sex-Specific Patterns.

Journal of the American Medical Directors Association·2026
Same author

Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.

Journal of Alzheimer's disease : JAD·2026
Same author

Sex differences in documented clinical features of memory clinic patients: a natural language processing study.

Cerebral circulation - cognition and behavior·2026
Same author

Factors associated with severe neurological sequelae of COVID-19: findings from the multicenter COVID-BRAIN imaging cohort.

Frontiers in human neuroscience·2026
Same author

Contingency of Plasma Dementia Biomarkers on Cognitive Profiles for Prognosis of Incident Dementia: The ARIC Study.

Neurology·2026
Same author

How to treat diabetes mellitus in the older patients: being risk averse versus being too progressive.

Expert review of endocrinology & metabolism·2026

Related Experiment Video

Updated: Jul 31, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Cardiovascular Risk Management in Persons with Dementia.

Charlotte Nijskens1, Marieke Henstra1, Hanneke Rhodius-Meester1,2,3

  • 1Department of Internal Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Geriatrics section, Amsterdam, The Netherlands.

Journal of Alzheimer'S Disease : JAD
|May 1, 2023
PubMed
Summary
This summary is machine-generated.

Cardiovascular risk management in dementia patients requires careful consideration of life expectancy and potential harms. Guidelines need adaptation to prevent adverse events and overtreatment in this population.

Keywords:
Alzheimer’s diseasecardiovascular diseasescardiovascular riskcontroldementiahypercholesterolemiahypertensionprevention

More Related Videos

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

621
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.6K

Related Experiment Videos

Last Updated: Jul 31, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

621
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.6K

Area of Science:

  • Gerontology
  • Neurology
  • Cardiology

Background:

  • Global increase in dementia prevalence, including Alzheimer's disease.
  • Individuals with dementia have elevated risk for atherosclerotic cardiovascular disease.
  • Current cardiovascular risk management guidelines exclude individuals with dementia.

Purpose of the Study:

  • To review and adapt current cardiovascular risk management guidelines for individuals with dementia.
  • To discuss considerations for treating hypertension and hyperlipidemia in dementia patients.
  • To prevent major adverse cardiovascular events (MACE) in this population.

Main Methods:

  • Narrative review of existing cardiovascular risk management guidelines.
  • Discussion of guideline applicability to individuals with dementia.
  • Analysis of factors influencing treatment decisions and monitoring.

Main Results:

  • Survival is shorter in persons with dementia, necessitating evaluation of life expectancy and treatment wishes.
  • Risk assessment tools may overestimate MACE risk and CVRM benefits in dementia.
  • Close monitoring is crucial due to high risk of adverse drug events and overtreatment.

Conclusions:

  • CVRM in dementia requires individualized approaches, prioritizing patient longevity and preferences.
  • Risk assessment tools should be used cautiously in this population.
  • Deprescribing should be considered for individuals with dementia and limited life expectancy.